YCYuan Chang

Yuan Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuan Chang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Jiejie Xu

    National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    14 shared publications
  • Zhaopei Liu

    Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    14 shared publications
  • Han Zeng

    Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    13 shared publications
  • Kaifeng Jin

    National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    13 shared publications
  • Zewei Wang

    Department of Urology Zhongshan Hospital Fudan University Shanghai China

    13 shared publications
  • Weijuan Zhang

    Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    12 shared publications

Latest Publications

  • TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma

    by Xiaohe Su, Kaifeng Jin, Han Zeng, Zhaopei Liu, Lingkai Zhang, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yuan Chang, et al.

    Background Emerging evidence has underscored non-cell-autonomous roles of mutant p53 in reshaping the composition and functional state of tumour immune microenvironment (TIME). However, the impact of p53 status on the clinical relevance and functional differentiation of CD8+ T cells remains poorly understood in urothelial carcinoma (UC). Methods Our study included 297 UC patients from two in-house cohorts and 871 UC patients from four public datasets to evaluate the impact of p53 status on the clinical implications of CD8+ T cells. Single-cell RNA sequencing, flow cytometry, immunohistochemistry, and bioinformatics analyses were performed to elucidate the role of p53 status in regulating CD8+ T cell polarisation and reshaping the TIME. Results High CD8+ T cell infiltration correlated with favourable prognosis and improved survival following chemotherapy and PD-(L)1 blockade exclusively in p53-WT UC, while its association with prognosis and therapeutic benefit was abrogated in p53-mutant UC. Moreover, p53-mutant UC exhibited predominant infiltration of TIM3+ exhausted CD8+ T cells, accompanied by increased Treg and M2 macrophage infiltration. Conclusions The clinical significance and functional polarisation of CD8+ T cells in UC varied in a context-dependent manner according to p53 status. These findings provide novel insights to refine patient stratification and optimise personalised therapeutic strategies.

  • Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma

    by Jiaxing Sun, Kaifeng Jin, Yawei Ding, Yuzhen Wu, Lingkai Zhang, Xiaohe Su, Jinming Shi, Zhaopei Liu, Han Zeng, Hailong Liu, et al.

    Background: Ki‐67 is routinely used in clinical practice to quantify proliferative activity, yet proliferation has not been incorporated into current molecular classification systems for urothelial carcinoma (UC). This work studies the tumor microenvironment (TME), therapeutic vulnerabilities, and clinical implications of the proliferative ecotype in UC. Methods: The authors assembled a multi‐cohort data set of 1431 UC patients from four institutional cohorts and five publicly available data sets with comprehensive clinicopathological annotations. Through an integrated multi‐omics framework coupled with experimental validation, they assessed how proliferative status shape lineage differentiation, clinical outcomes, treatment response, and TME architecture. Results: High Ki‐67 expression identified a proliferative ecotype associated with markedly worse prognosis but enhanced sensitivity to platinum‐based chemotherapy and PD‐1/PD‐L1 blockade. This ecotype displayed elevated tumor purity and tumor mutation burden, with characteristic genomic alterations including enrichment of TP53 , ERCC2 , and ATM/RB1/FANCC mutations and reduced 9p21.3 loss. The proliferative ecotype orchestrated an immune‐enriched TME dominated by CD8 + T cells and B cells. Functional analyses revealed that CD8 + T cells preferentially differentiated toward an exhausted state, and mechanistic interrogation identified a GDF‐15–TGFBR2 signaling axis through which epithelial cells modulate CD8 + T‐cell dysfunction. Conclusions: This study identifies a proliferative ecotype of UC that is orthogonal to classical luminal/basal ecotypes. Despite its adverse prognosis, this ecotype confers superior responsiveness to chemotherapy and immunotherapy and features a distinct genomic and immune ecosystem. These findings position proliferative status as a clinically actionable axis that may refine molecular classification and guide precision therapy in UC.

  • Open Access

    Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma

    by Yawei Ding, Kaifeng Jin, Xiaohe Su, Lingkai Zhang, Zhaopei Liu, Jiaxing Sun, Yuzhen Wu, Jinming Shi, Han Zeng, Hailong Liu, et al.

    Background: Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but also as a potential architect of the tumor immune microenvironment (TIME). However, how aberrant p53 status, comprising TP53 mutation ( TP53 Mut ) and p53 abnormal expression (p53 Abn ), correlates with TAM phenotypic and functional heterogeneity and their reciprocal interactions within the TIME landscape remains incompletely defined. Methods: This study integrated single-cell RNA sequencing, immunohistochemistry, and flow cytometry to delineate TAM phenotypes and map distinct immune landscapes stratified by p53 status. Clinical relevance was assessed in a multicohort dataset of 962 patients with UC with comprehensive clinicopathological annotations. Results: Single-cell profiling revealed distinct TAM subsets closely linked to p53 status. Interferon-primed TAMs, marked by CXCL9 , CXCL10 , CXCL11 and IDO1 , predominated in p53 wild-type (p53 WT ) tumors, whereas immune regulatory TAMs (Reg-TAMs), marked by SPP1 , MARCO , SLC2A1 and INHBA, were enriched in p53 Abn tumors. This divergent distribution highlighted a profound, p53-associated TAM heterogeneity. Clinically, high TAMs infiltration was consistently associated with worse overall survival predominantly in p53 Abn or TP53 Mut patients across three independent cohorts (Zhongshan Hospital, Fudan University Shanghai Cancer Center and The Cancer Genome Atlas). Furthermore, high TAMs infiltration correlated with poorer responses to both platinum-based chemotherapy and anti-programmed cell death-ligand 1 immunotherapy specifically in the p53 Abn or TP53 Mut subgroup. Notably, aberrant p53 status was strongly coupled with a distinct metabolic reprogramming in TAMs, favoring lipid catabolism and immunoregulatory polarization. Trajectory analysis revealed a skewed differentiation axis in p53 Abn tumors toward terminally differentiated Reg-TAMs. Immunohistochemistry and flow cytometry validated increased immunosuppressive TAM subsets in p53 Abn UC. Additionally, p53 Abn tumors exhibited an altered CD4 + T-cell landscape, enriched for suppressive subsets (regulatory, exhausted, and metallothionein-expressing T cells) coexisting with Reg-TAMs, potentially associated with immune suppression via the predicted SPP1-CD44 axis. Conclusions: In UC, aberrant p53 status correlates with a remodeled TIME, characterized by metabolically reprogrammed, immunosuppressive TAMs. These TAMs co-evolve with suppressive CD4 + T cells, suggesting a coordinated immunosuppressive network potentially involving SPP1-CD44 signaling. Together, this specific genotype-phenotype coupling delineates a profoundly immunosuppressive ecosystem that likely impedes immune clearance and limits therapeutic efficacy.


  • Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma

    by Lingkai Zhang, Zhaopei Liu, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Xiaohe Su, Kaifeng Jin, Han Zeng, Hailong Liu, Yuan Chang, et al.

    Background: Sex differences are a hallmark of urothelial carcinoma (UC), and profoundly influence disease progression and therapeutic outcomes. As critical effector immune cells with intrinsic sexual dimorphism, the contributions of natural killer (NK) cells to this clinical discrepancy remain incompletely understood. Methods: In this multicohort retrospective study of 885 patients with UC (671 males; 214 females), individuals were stratified into NK high and NK low subgroups on the basis of immunohistochemical or transcriptomic evaluation. The association of NK cells with clinical outcomes and the tumor immune microenvironment (TME) was systematically assessed across sexes. Single‐cell RNA sequencing and flow cytometry were deployed to decipher the functional state of NK cells. Results: Although NK cell infiltration levels were comparable between sexes, their clinical impact was markedly divergent: high NK infiltration conferred a significant survival advantage and superior response to both chemotherapy and immunotherapy exclusively in male patients. Further immune profiling revealed that NK high male patients exhibited a coordinated antitumor microenvironment, characterized by immunotype A features, tertiary lymphoid structure formation, and abundant infiltration of dendritic cells and effector T cells. Mechanistically, male‐derived NK cells maintained robust cytotoxic and inflammatory programs, whereas female‐derived NK cells were polarized toward a stressed, dysfunctional state with decidual‐like characteristics. Conclusions: Altogether, this study establishes NK cells as pivotal mediators of sex differences in UC. The stark contrast in NK cell phenotypes underscores a fundamental sexual dimorphism within the TME, which highlights the urgent need for sex‐tailored immunotherapy strategies.


  • Open Access

    Supplementary Table S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Details of immunohistochemistry antibodies.

  • Open Access

    Data from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Purpose:ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood.Experimental Design:The clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients.Results:ARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4.Conclusions:The combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.

  • Open Access

    Supplementary Figure S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Representative IHC images of ARID1A and CD8+ T cells in UC.

  • Open Access

    Supplementary Figure S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Enrollment, clinicopathological features and inclusion criteria for ZSHS, FUSCC, and Shanghai-sequencing cohorts.

  • Open Access

    Supplementary Table S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Sources and details of the utilized gene signatures.

  • Open Access

    Supplementary Figure S4 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Association between ARID1A status and CD8+ T cell signature in the IMvigor210 cohort.